Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-DR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-DRA/DRB1 Heterodimer Protein Co-expressed alpha/beta chains, HEK293 expressed, High purity (>95%), Endotoxin controlled. Sequence Verified. |
View HLA-DRA Products |
| Gene Delivery | HLA-DRA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to preserve native heterodimeric conformation. |
View HLA-DRA Products |
| Benchmark Ab | Anti-HLA-DR Recombinant Antibody Sequence derived from clinical benchmark (e.g., L243/Immu-114 clone) for positive control. |
View HLA-DRA Products |
| Validator | HLA-DRA siRNA Set For target knockdown and specificity verification in cell-based assays. |
View HLA-DRA Products |
| Related Target A | LAG3 Key immune checkpoint receptor that directly binds to MHC Class II (HLA-DR) to mediate T-cell exhaustion. |
View LAG3 Products |
| Related Target B | CD4 Co-receptor on T helper cells interacting with HLA-DR to stabilize TCR-MHC II engagement. |
View CD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MHC II Heterodimer Instability | Co-expressed HLA-DRA and HLA-DRB1 chains with optimized peptide linkers to ensure stable heterodimerization. |
| Allele Polymorphism Screening | HLA-DRA paired with major clinical DRB1 alleles (e.g., DRB1*01:01, DRB1*15:01) verified by mass spectrometry. |
| Lack of Controls | Recombinant benchmark antibodies (L243-derived) included for assay standardization. |
| Conformation-dependent Binding | Lentivirus-mediated stable cell lines provide native-state cell-surface conformation for flow cytometry. |
Live HLA-DR/HLA-DRA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HLA-DR (MHC Class II) is undergoing a major renaissance. Historically targeted for direct tumor lysis in hematological malignancies, HLA-DR is now a focal point in the LAG-3/MHC-II immune checkpoint axis. The race for HLA-DR therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to bispecific antibodies (e.g., targeting HLA-DR and CD3 or tumor-associated antigens) and targeted autoimmune tolerogenic therapies. As first-generation global therapies reach mature clinical phases, the next wave of R&D is targeting allele-specific HLA-DR interactions and pH-dependent binding kinetics to minimize systemic toxicity on healthy antigen-presenting cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibodies | Roche, Boehringer Ingelheim | Solid Tumors, Lymphoma | Heterodimer Validation (Need cross-reactive, highly stable HLA-DRA/DRB1 heterodimers) |
| Monoclonal Antibodies | Immunomedics (Gilead) | CLL, Non-Hodgkin Lymphoma | Internalization & ADCC Assay (Need sequence-verified benchmark antibodies) |
| Tolerogenic Vaccines / Peptides | Selecta Biosciences, Apitope | Multiple Sclerosis, Rheumatoid Arthritis | Peptide-Exchange & Binding Assays (Need allele-specific recombinant HLA-DR complexes) |